Michael R. Grunwald
YOU?
Author Swipe
View article: The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission
The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission Open
Introduction: Genetic profiling is essential for optimal management of patients with acute myeloid leukemia (AML). Whole genome sequencing (WGS) has been proposed as a replacement for the multiple testing modalities currently in use but ha…
View article: A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)
A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV) Open
Background and Significance: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with pathologic erythrocytosis, most often driven by somatic mutations in the JAK2 gene. A key treatment goal is maintaining hematocrit (HCT) b…
View article: Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL
Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL Open
Background: Molecular markers associated with PV progression to myelofibrosis (MF) or acute myeloid leukemia (AML) remain limited. The Prospective Observational Study of Patients (Pts) With Polycythemia Vera in US Clinical Practices Trial …
View article: Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML
Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML Open
Opinion statement The integration of next-generation sequencing (NGS) and advanced cytogenetic diagnostics into routine clinical practice is reshaping frontline treatment of acute myeloid leukemia (AML) in both fit and unfit patients. Mole…
View article: Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis Open
Whether older HLA-matched sibling donors (MSD) are preferred over younger alternative donors for allogeneic hematopoietic cell transplantation (allo-HCT) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) pr…
View article: Editorial: Molecular MRD testing in patients with acute myeloid leukemia
Editorial: Molecular MRD testing in patients with acute myeloid leukemia Open
View article: Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial Open
Importance Patients requiring allogeneic hematopoietic cell transplantation have variable likelihoods of identifying an 8/8 HLA-matched unrelated donor. A Search Prognosis calculator can estimate the likelihood. Objective To determine if u…
View article: Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis
Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis Open
Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with E…
View article: Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study Open
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In a…
View article: Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice Open
View article: Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice Open
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin (HGB) and/or hematocrit (HCT). Patients often have clinical symptoms such as fatigue, pruritus,…
View article: Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL Open
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by clonal proliferation of hematopoietic progenitor cells and is associated with an increased risk of thrombotic events (TEs). Established risk factors for TEs in patien…
View article: Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis Open
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell trans…
View article: Top advances of the year: Myeloproliferative neoplasms
Top advances of the year: Myeloproliferative neoplasms Open
The rapid pace of drug development in hematology has led to multiple approvals for myelofibrosis (MF) and polycythemia vera (PV) in recent years. Moreover, there are many innovative agents and combinations being explored for myeloprolifera…
View article: POSTER: MPN-540 Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
POSTER: MPN-540 Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) Open
View article: POSTER: MPN-574 Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL)
POSTER: MPN-574 Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL) Open
View article: MPN-540 Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
MPN-540 Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) Open
View article: P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: ET is characterized by uncontrolled platelet (PLT) production and clonal hematopoiesis leading to increased risk of vascular complications and high symptom burden. In patients …
View article: P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST
P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Progressive disease (PD) in myelofibrosis (MF) is associated with increased bone marrow fibrosis, worsening anemia, and increased circulating blasts, and can result in leukemic…
View article: P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL
P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Resistance or intolerance to first-line hydroxyurea (HU) occurs in ~24% of patients (pts) with polycythemia vera (PV); ruxolitinib (RUX) is a recommended second-line treatment …
View article: Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration Open
Haploidentical donors offer a potentially readily available donor, especially for non-White patients, for hematopoietic cell transplantation (HCT). In this North American collaboration, we retrospectively analyzed outcomes of first HCT usi…
View article: Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing Open
CYP2C19 -guided voriconazole dosing reduces pharmacokinetic variability, but many patients remain subtherapeutic. The aim of this study was to evaluate the effect of candidate genes and a novel CYP2C haplotype on voriconazole trough concen…
View article: A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis Open
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the…
View article: Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report Open
Supplementary Material
View article: Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report Open
Purpose:To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation…
View article: Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report Open
Supplementary Material
View article: Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report Open
Purpose:To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation…
View article: COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients
COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients Open
Overall, vaccine uptake was low among our cohort of previously infected cancer patients. Older age, female sex, and higher income were the only variables associated with COVID-19 vaccine uptake within this vulnerable patient population.
View article: Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients
Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients Open
View article: Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration Open
Haploidentical donors offer a potentially readily available donor, especially for non-White patients, for blood or marrow transplantation (BMT). In this collaboration across North America, we retrospectively analyzed outcomes of first BMT …